ExCulture secures funding

1 oktober 2024

PLNT startup ExCulture B.V., which focuses on the development of an animal-free heparin replacement via fermentation, is proud to announce that it has closed its latest round of investment with Capricorn Partners and TTT Medtech.

 

The investment allows ExCulture to continue comparison studies between porcine heparin and ExCulture’s heparin substitute according to pharmacopoeia guidelines. This is essential for advancing the regulatory pathway.

New investment round

The investment round was funded by the Dutch Industrial Biotech Seed Fund, managed by Capricorn Partners’ Cleantech Team, and Medtech TTT, a national platform managed by Innovation Industries.

 

This funding complements funds obtained by ExCulture in 2023 from UNIIQ, Delft Enterprises (Delft University of Technology) and Libertatis Ergo Holding (Leiden University). Each of the existing and new investors brings a broad network and valuable expertise ranging from industrial biotechnology to pharmaceutical development.

 

With this new funding, ExCulture will:

  • Improve product development: Continue chemical and biological characterization studies to advance regulatory development and meet market requirements.
  • Scale up production: Optimize the bioprocess and prepare for pilot scale production.
  • Expand research: Invest in research and development to explore additional applications of their fermentation platform technology and increase its impact.

ExCulture's mission

Aisling Foley, co-founder and CEO of ExCulture, highlights how the mission of ExCulture’s newest investors – to support emerging, innovative technologies – aligns perfectly with ExCulture’s ambitions; “Heparin is the most widely used blood thinner in the world, so it’s surprising that in the 21st century such an essential drug is still produced as a byproduct of pig slaughter. This method of production has led to global shortages since 2017 and has exposed the supply chain to contamination crises in the past. ExCulture’s goal is to use our new, animal-free bioprocess to produce a safer product through a more sustainable process. Ultimately, we aim to create a more future-proof method of biopharmaceutical production.”

Share this article

View all latest articles

28 augustus 2026
Axite Data Scientist Discusses the Future of EEG
On Thursday, August 20, Dirk van Moorselaar of PLNT spin-off Axite joined Ron Le...
5 augustus 2026
Bionomic on New Business Radio Live!
On Thursday, July 30, Diederik Mud, CEO and co-founder of PLNT spin-off Bionomic...
5 augustus 2026
Record investments don’t tell the whole story
On Thursday, July 23, our CEO Bastiaan de Roo was a guest on New Business Radio ...
21 juli 2026
GenLumina switches off cancer with light
Current cancer treatments often kill many healthy cells alongside cancer cells. ...
6 juli 2026
80% of quantum chips fail, QuantaMap is committed to changing that
Quantum chips are getting better and better, but no one understands exactly why ...
11 juni 2026
Co-founding the right way with Dr. Jana Nevrlka
On June 11, PLNT welcomed Dr. Jana Nevrlka for a special program day organized b...
28 mei 2026
Akin Solutions is moving to Delft!
After a valuable period within our community, Akin Solutions is taking another s...
21 mei 2026
Gateway Bio wins Audience Award and Rough Diamond Award at the Philips Innovation Awards!
Cool news! Gateway Bio, startup from the unlock_ cohort 2026-2027, won both the ...
12 mei 2026
The new unlock_ cohort has started
As of April, the new unlock_ cohort has begun. Ten Live Sciences & Health st...
16 april 2026
unlock_ cohort 2025-2026 has passed!
Yesterday was the official graduation of the unlock_cohort 2025-2026! The startu...
6 maart 2026
Radigene aims to take cell and gene therapy out of the ‘black box’
Cell and gene therapies offer enormous opportunities for patients with serious d...
2 maart 2026
Gulliver Startup Awards 2026
On Friday, February 27, the festive finals of the Gulliver Startup Awards took p...